Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Fecal occult blood and calprotectin testing to prioritize primary care patients for colonoscopy referral: The advantage study

  • Lanas, Ángel
  • Balaguer, Francesc
  • Sánchez-Luengo, Marta
  • Hijos-Mallada, Gonzalo
  • Hernández-Mesa, Goretti
  • Piñero, Melisa
  • Castillo, Joaquin
  • Ocaña, Teresa
  • Cubiella, Joaquín
  • Crespo, Anais
  • Iglesias, Águeda
  • Medeiros, Isabel
  • Cacho, Guillermo
  • Jover-Martínez, Rodrigo
  • Alustiza, Miren
  • Diaz-Tasende, José
  • Poves, Carmen
  • Macedo, Guilherme
  • Quintero, Enrique
AbstractColonoscopy is the gold standard for colorectal cancer (CRC) diagnosis and screening, but endoscopy services are usually overburdened. This study aims to investigate the usefulness of fecal hemoglobin (fHb) and calprotectin (FC) for the identification of patients with high probability of CRC who need urgent referral.MethodsIn a multicenter prospective study, we enrolled symptomatic patients referred from primary care for colonoscopy. Prior to bowel preparation, fHb and FC quantitative tests were performed. The diagnostic performance was estimated for each biomarker/combination. We built a multivariable predictive model based on logistic regression, translated to a nomogram and a risk calculator to assist clinicians in the decision‐making process.ResultsThe study included 1224 patients, of whom 69 (5.6%) had CRC. At the fHb cut‐offs of >0 and 10 μg/g, the negative predictive values for CRC were 98.8% (95% confidence interval 97.8%–99.3%) and 98.6% (95%CI 97.7%–99.1%), and the sensitivities were 85.5% (95%CI 75.0%–92.8%) and 79.7% (95%CI 68.3%–88.4%), respectively. When we added the cut‐off of 150 μg/g of FC to both fHb thresholds, the sensitivity of fecal tests improved. In the multivariate logistic regression model, the concentration of fHb was an independent predictor for CRC; age and gender were also independently associated with CRC.ConclusionsfHb and FC are useful as part of a triage tool to identify those symptomatic patients with high probability of CRC. This can be easily applied by physicians to prioritize high‐risk patients for urgent colonoscopy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Complete loss of epcam immunoexpression identifies epcam deletion carriers in msh2negative colorectal neoplasia

  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • Gorostiaga, Iñigo|||0000-0003-0359-9963
  • Riera, Cristina|||0000-0002-3522-5598
  • Saperas, Esteban
  • Llort, Gemma|||0000-0001-9987-7862
  • Costa, Irmgard|||0000-0001-5760-8293
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Carrato, Cristina|||0000-0002-1953-8287
  • Navarro, Matilde Y.
  • Pineda, Marta|||0000-0002-5403-5845
  • Dueñas Cid, Nuria|||0000-0001-6624-3265
  • Brunet, Joan|||0000-0003-1945-3512
  • Marco-Molina, Vicente
  • Trias, Isabel|||0000-0001-9841-4380
  • Busteros-Moraza, José Ignacio
  • Mateu, Gemma
  • Balaguer, Francesc|||0000-0002-0206-0539
  • Fernández-Figueras, Maria Teresa|||0000-0002-2366-7110
  • Esteller, M.|||0000-0003-4490-6093
  • Musulén, Eva|||0000-0002-9667-6464
The use of epithelial cell adhesion molecule (EPCAM) immunohistochemistry (IHC) is not included in the colorectal cancer (CRC) screening algorithm to detect Lynch syndrome (LS) patients. The aim of the present study was to demonstrate that EPCAM IHC is a useful tool to guide the LS germ-line analysis when a loss of MSH2 expression was present. We retrospectively studied MSH2 and EPCAM IHC in a large series of 190 lesions composed of malignant neoplasms (102), precursor lesions of gastrointestinal (71) and extra-gastrointestinal origin (9), and benign neoplasms (8) from different organs of 71 patients suspicious of being LS due to MSH2 alterations. LS was confirmed in 68 patients, 53 with MSH2 mutations and 15 with EPCAM 3'-end deletions. Tissue microarrays were constructed with human normal tissues and their malignant counterparts to assist in the evaluation of EPCAM staining. Among 154 MSH2-negative lesions, 17 were EPCAM-negative, including 10 CRC and 7 colorectal polyps, and 5 of them showed only isolated negative glands. All lesions showing a lack of EPCAM expression belonged to patients with EPCAM 3'-end deletions. EPCAM IHC is a useful screening tool, with 100% specificity to identify LS patients due to EPCAM 3'-end deletions in MSH2-negative CRC and MSH2-negative colorectal polyps.